Daniel Wang
Director, Cannabinoids and New Dietary Ingredients
Helping clients advance their ideas and bring meaningful innovative products to consumers
Expertise
Daniel (Dan) applies his extensive knowledge of the regulatory and policy environment for CNS-active compounds to the development of CBD, other cannabinoids, and novel dietary ingredients. In this role, Dan focuses on:
- Regulatory strategy and pathways
- New Dietary Ingredients Notification (NDIN) process
- Abuse potential assessment
- Data gap analysis
Experience
Before joining Pinney Associates in 2010, Dan coordinated early-phase clinical trials in oncological drug development at the Hospital of the University of Pennsylvania.
At Pinney Associates, Dan has spent more than ten years providing scientific and regulatory background for companies developing and marketing drugs and other products with potential for abuse. He has presented and co-authored a number of articles on the abuse potential of novel botanical products, including kratom, and on the real-world outcomes of the use of these products.
Education
BA, Biological Basis of Behavior, University of Pennsylvania
